Celosia Therapeutics begins Phase 1b trial of CTx1000 for ALS
Celosia Therapeutics has initiated a pivotal Phase 1b trial, KOANEWA, by dosing its first participant with CTx1000, a novel genetic therapy targeting amyotrophic lateral sclerosis (ALS). Conducted at Macquarie University Hospital in Sydney, this open-label study aims to evaluate the safety and tolerability of a single administration of CTx1000, while also incorporating biomarker profiling and clinical measures as exploratory efficacy endpoints.
This trial is significant for the longevity and healthspan field as it represents a potential breakthrough in ALS treatment, focusing on the pathological TDP-43 protein, which is central to the disease’s progression. The investigational therapy stems from a 2024 discovery by Neuron and has demonstrated promising results in preclinical models, where it halted disease progression and even partially reversed symptoms in some cases.
For professionals in the aging biology and therapeutic development sectors, the progression of CTx1000 offers a concrete example of how genetic medicine can address neurodegenerative diseases, potentially reshaping treatment paradigms for ALS and similar conditions.